Crowdfunding an Investment in Therapeutic Healing
Limited Chance for Investors Looking for a Potential Biotech Windfall: The Future of Healing
45% of the deaths in the industrialized world, according to the National Library of Medicine, stem from a single condition: fibrosis.[1]
Yet what you’re about to see…
Could help make that a thing of the past, thanks to an under-the-radar firm that could quickly catch the attention of Big Pharma.
Its treatments could usher in a futuristic world of healing.
Where not only millions of deaths from fibrosis could be a thing of the past…
But also advancing mankind forward to a newer, faster form of healing their bodies and reversing damage. Helping those with …
Reversing Type 1 diabetes…potentially for millions with a single short-term treatment![2]
Alopecia Areata[3]… 160 million people suffering from … this distressing, psychosocial autoimmune hair loss disorder …
And the countless number of us who have scars on our skin…
All from a cutting-edge form of healing… one that Business Insider calls, “first-of-its-kind” and “groundbreaking”.[4]
Most people, with the exception of a few majors in the biotech industry, don’t have a clue it exists and is ready to go to market with its cosmetic products.
Then again… most don’t understand just how fast medicine is progressing.
The FDA is currently fast-tracking drugs faster than ever.[5]
AI is literally inventing potential new drugs as MIT recently unveiled.[6]
All of this means the pipeline from discovery to drug is moving quicker than ever.[7] What used to take years… now takes a fraction of that time.
Which is why many of the top biotech companies in the world are now in overdrive mode. And investors need to be taking note of this.
A small stake today… in the right companies… pioneering the right cures….
It could be the equivalent to penicillin being discovered by Alexander Fleming 100 years ago.[8]
Biotech is what minted the world’s first billionaire.[9] Which is why it’s no surprise many of today’s billionaires are rushing back in, to expand their empires even more.[10]
And today, a unique opportunity has emerged once again…
A company is introducing the future of healing…
This company is currently seeking to raise $10 million and a potential direct listing on the NASDAQ.*
The profit ramifications could be enormous … especially for a scrappy company.
Its treatments could:
- Help prevent up to 45% of the deaths in the industrialized world… unlocking up to $96 billion in total addressable market value… [11]
- Reverse Type 1 Diabetes… for which there is no cure and is increasing year over year.[12a] – an $8 billion market.[12b]
- Potentially cure autoimmune disorders such as alopecia areata – a potential $22 billion market.[13]
Several leading cosmetic and over-the-counter companies are already discussing how a non-prescription strength version of this scar treatment could benefit their customers.
- This young company could completely disrupt the scar treatment industry – a $2.3 billion market.[14]
- And the beauty market, valued at $114 billion in America alone.[15]
And this is not a what if scenario.
Discussions with major cosmetics companies are already in motion.
Clinical trials have already progressed significantly … some having completed phase 2 and others on their way to Phase 3.[16] And as mentioned earlier, the FDA is greenlighting more medicines than ever in the phase 3.[17]
So if you’re ready to find out about the future of healing, BirchBioMed, a company that could soon be a HUGE player in the world of biotech, should be on your radar
See for Yourself The Future Healing
Those who’ve carried a scar know how embarrassing and confidence killing it can be.
A before and after picture is all it takes to understand BirchBioMed is doing something uniquely ground-breaking.
Internationally recognized burn surgeon Anthony Papp, the doctor who evaluated this treatment during its phase studies, revealed to News Wire:
“As a burn surgeon, I see the horrific effects of scarring every day… There is no therapeutic on the market today that has shown the unequivocal results that FS2 has demonstrated in robust pre-clinical scar models.”[18]
And this is not just burns.
Post op scar tissue has also responded to their treatment…
As well as mature scar tissue that had been in place for months and years.
Meaning for the billions of people who have a childhood scar… or suffered a workplace accident they wish they could forget… or just carry a reminder of a past surgery… the option to remove it through a natural healing process being pioneered by this firm could be in store…
And the applications go far beyond just scar tissue.
Few outside the medical field know this, but over 45% of the deaths in the industrialized world are caused by severe fibrosis.[19] This includes everything from the heart, lungs, liver, the intestinal tract… even the skin and nervous system.
The fact is that BirchBioMed has come up with something that could drastically reduce fibrosis. This technology is starting to put them on the radar of Big Pharma globally.
The reason they have the potential to reduce the global-killer that is fibrosis so amazingly is thanks to an incredible new, patent-protected science called FS2.
This is a naturally occurring molecule in the healing process. One that signals the body to stop the formation of scars and to break down existing scars.
FS2 has also prevented buildup of scar tissue nodules in the lungs as you can see here.
FS2 is also showing promising results to help cure autoimmune disorders, such as Type 1 Diabetes and Alopecia Areata (autoimmune hair loss).
Imagine a world where diseases once considered insurmountable obstacles are mere bumps in the road on the path to wellness.
And now imagine if you, as an investor, had access to become a shareholder BEFORE the company went public.
Before the company disrupts the healing process of virtually every scar remedy in the modern medical world.
Moments like these are rare for biotech investors.
Just consider if you’d invested $1,000 into Johnson and Johnson at the very beginning, when they IPO’d … that small bet would have paid off massively with a $10 million fortune.[21]
Pfizer has gone from 27 cents at IPO to more than $27 today; handing early investors over 100 times their money.[22]**
When you get in on the right company, the long-term benefits can be life-changing.
With this many applications, the company is compelling not only from an investing standpoint, but even from an M&A standpoint.
Any one of the Big Pharma names could buy up this company with a single stroke of one of their accountant’s pens.
Making this limited window that you have to get in pre-public listing potentially very impactful for you as an investor.
Because this truly is The Future of Healing …
Imagine walking into a CVS or a Walgreens …
Seeing this company’s technology on the shelves, side by side along giants like Johnson and Johnson, Pfizer and Bristol Meyers Squibb… knowing that you had the chance to invest before this company could go public.*
This could very well be one of the most profitable investments you ever stumble upon, just due to the sheer variety of all its applications.
Soon it could spread to doctors’ offices, hospitals, outpatient treatment, cosmetic surgeons offices and beyond… unlocking the potential of this $96 billion market.
For investors, this could be the final opportunity to invest in BirchBioMed before going public.
The company is only looking to raise $10 million before its planned listing on the NASDAQ.
And raising $10 million is not outside the experience of this company …
Quite the contrary, BirchBioMed is used to cashing millions of dollars in checks coming their way…
The Power of Partnership and a Stacked Board
BirchBioMed has received over $6 million in grants and donations, including from the Canadian Institute of Health Research, Juvenile Diabetes Research Foundation, National Alopecia Areata Foundation, WorkSafeBC (British Columbia) and some of the world’s major firefighters associations.[23]
The Canadian Government has played an instrumental role in supporting BirchBioMed! The Canadian government spends $8,500 per Canadian resident on healthcare, for a whopping $330 billion, so if they can get that number lower with a company like BirchBioMed, it’s a win-win for everyone.[24]
It’s no accident they’re coming into these millions: the company is spearheaded by one of the most stacked management boards in the industry.
Doctors, former CEOs of biotech companies and C-suite executives of major pharma companies, even combat experienced military doctors.
In short, the team isn’t just led by flashy suits trying to drive a medicine to market – it’s led by medical professionals who understand what the majority of patients want and need
It’s led by proven C-level executives who know what it takes to take biotechs public.
And most importantly for investors, by a management team that has shown results.
But this opportunity will not remain open forever. Time is ticking on the chance to get in on this round of funding before the company’s planned public listing.
Once the company hits its $10 million funding round, that’s it. Your chance to get in on this round will be gone forever.
Limited Chance for Smart Investors to Get in Before Public Listing
If you get in on the bare minimum round of funding, it’s no stretch that $1,000 could change your life.
If you agree that BirchBioMed could be onto something big, you should consider investing before this round of funding closes.
If you’ll remember earlier… just $1,000 into JNJ at their IPO yielded more than $10,000,000 over the course of time.[25]
Pfizer turned every $1,000 invested into $100,000!
Of course, past performance is no guarantee of future results.
But with nothing else like this on the market, investors who are interested in potential biotech fortunes should keep BirchBioMed on their radars.
All you have to do is get in during this round of crowdfunding, during the Reg A phase.
If you’re unfamiliar with Reg A deals…
This is one of the best ways for everyday investors to get into pre-public companies like BirchBioMed and the future of healing.
Since first becoming an option for investors 12 years ago, Reg A deals like this have been the ultimate way for small startups to raise up to $50 million.[26]
Not to mention, the company already has the attention of major name brand cosmetics companies that have expressed interest in this anti-scarring treatment for their customers.
The signs are pointing to an exciting industry shift – and this company could be a major winner.
BirchBioMed is on track to revolutionize not just the future of healing, but the landscape of diabetes treatment, alopecia areata and more.
The reasons to keep this company on your radar as an investor seem almost endless.
5 Reasons to Invest in BirchBioMed Right Now
-
Groundbreaking Innovation: BirchBioMed's revolutionary treatment, FS2, isn't just another product in the market. Business Insider has called it one of a kind and rightfully so: It has the potential to transform lives across multiple medical fronts[27]. With its potential ability to accelerate healing, prevent scarring, and address a spectrum of ailments from fibrosis to autoimmune disorders, FS2 represents a breakthrough that could redefine medical treatment paradigms.
-
Explosive Market Potential: BirchBioMed's FS2 isn't just limited to medical applications; it could be poised to revolutionize the $2 billion scar treatment industry as well.[28]
The release of an OTC version of FS2 could be backed by a major industry player. This could herald a new era in cosmetic products entirely.
-
Exponential Growth Projections: Even a conservative estimate of BirchBioMed capturing just one percent of its addressable market translates into substantial growth.
-
Upcoming NASDAQ Listing*: BirchBioMed intends to begin their journey to the NASDAQ in the near-future.
As BirchBioMed prepares to make its mark on one of the world's most prestigious stock exchanges, investors have a unique chance to get in on the ground floor of a biotech revolution with huge potential.
So as this stock captures the attention of the biotech industry, you’ll already be in before almost anyone else.
-
Private Equity Outperforms Public Markets: research has shown throughout time that private equity has outperformed public markets.[29] This is an exciting chance to get in on a biotech that is capturing the attention of Big Pharma and cosmetics giants alike.
Game-changing technology, expansive market potential, and life-saving impact, BirchBioMed presents a rare investment opportunity that demands attention.
Don’t miss out on being part of this transformative journey. Invest in BirchBioMed today and you could be a catalyst for change in the world of biotech and cosmetics.
This is your chance to get in before it goes public and potentially turn something as small as $1,000 into a windfall.
Don’t miss out on this round of funding for BirchBioMed before it closes.
*Listing on the NASDAQ pending approval
**Past performance is not indicative of future results. Birch BioMed cannot guarantee returns or future growth.
Terms
- Security type: Common shares
- Security price: $5
- Ancillary fee: 3.5%
- Minimum investment amount: $1,000 (200 common shares)
Investor Education
FAQs
- What is your commercialization strategy?
We provide an outline of our go-to market and commercialization approach in our most recent investor deck that can be found on our website. - What is your exit strategy?
We are a technology-transfer company. As such, we have been focused on developing our technologies to the point that they are prime candidates for M&A (Mergers and Acquisition) or out-licensing. Our exit strategy in the future could be a public offering (IPO) or M&A. We will share any information that can be made public with insider investors first. While we are under certain confidentiality agreements and SEC regulations that prohibit us from disclosing certain information, we kindly ask that you refer to the list of BirchBioMed™ SEC filings on EDGAR, including the filings that relate directly to the Regulation A+ offering. - Who are your current business contacts?
Most of our customer relationships are under NDAs and confidentiality agreements. That said, we are in discussions with several top-tier cosmetics and pharmaceutical companies about potential M&A or out-licensing. As soon as we are able to make public announcements, we will share this with our insider investors first. - Where can we access the company financials?
All of our financials are public information. You can find our most recent financials, along with our other recent updates on BirchBioMed™ SEC’s EDGAR webpage. - What are your plans for an IPO?
We are a private, pre-IPO company with no exchange on which to trade shares. Upon completion of our Regulation A+ offering, we intend to explore several potential go-public possibilities, such as listing on a public exchange (e.g., the Nasdaq). Upon approval from the SEC to list, our shareholders would be free to sell their shares. At this point, however, there is no set date for such a listing or any follow-on offerings. We will continue to include any new details that can be shared regarding developments in email updates to investors. - How do I access information on the shares I purchased?
You can access all investment information, including number of shares and DRS statement paperwork by logging into the portal by which you made your investment. If you need any changes, such as a beneficiary address change, please contact: https://odysseycontact.com/ if you made your investment through DealMaker.
Click I am a Shareholder or the holder of other Securities
Then choose the subject of the inquiry.
You may also call us 1-866-350-1993. - With the Regulation A+ offering, can I cash out whenever I want to?
At this time, no, as we are still a private, pre-IPO company with no exchange on which to trade shares. - How has BirchBioMed™ share price changed over time?
2016 Private Placement Shares (Regulation D) $1.00 per share
2020 Private Placement Shares (Regulation D) $2.00 per share
2023 Convertible Note Warrants (Exercise Price) $2.50 per share
2024 Current Offering (Reg. A+) $5.00 per share
Want to learn more about BirchBioMed's Breakthrough Therapeutic Healing?
By signing up above you will receive the free report and investor updates from BirchBioMed.
You can unsubscribe at any time..
Sources
[1] https://pubmed.ncbi.nlm.nih.gov/33239795/
[2] https://www.cdc.gov/diabetes/data/statistics-report/index.html
[3] https://www.pfizer.com/disease-and-conditions/alopecia-areata#:~:text=In%20total%2C%20an%20estimated%206.7,people%20globally%20have%20alopecia%20areata.&text=This%20condition%20affects%20some%20populations,have%20it%20than%20white%20people.
[4]https://markets.businessinsider.com/news/stocks/birchbiomed-is-cleared-to-begin-first-of-its-kind-phase-ii-clinical-trial-for-ground-breaking-anti-scarring-drug-1016018500?op=1
[5] https://www.advisory.com/daily-briefing/2019/07/10/fast-tracked
[6] https://www.technologyreview.com/2023/02/15/1067904/ai-automation-drug-development/
[7] https://www.nature.com/articles/s41587-024-02166-7
[8] https://www.sciencemuseum.org.uk/objects-and-stories/how-was-penicillin-developed#:~:text=In%201928%20Dr%20Alexander%20Fleming,chemical%20that%20could%20kill%20bacteria.
[9] https://www.fool.com/investing/general/2013/09/28/the-birth-of-pharmaceuticals-and-the-worlds-first.aspx
[10] https://investorplace.com/2024/03/billionaires-biotech-bets-3-stocks-dominating-bill-gates-portfolio/
[11] Investor Deck – Page 11
[12a] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10141720/#:~:text=The%20worldwide%20incidence%20of%20type,are%20not%20yet%20fully%20understood.
[12b]
https://www.expertmarketresearch.com/reports/type-1-diabetes-market
[13] https://www.futuremarketinsights.com/reports/alopecia-treatment-market
[14] https://www.grandviewresearch.com/industry-analysis/scar-treatment-market
[15] https://www.mckinsey.com/industries/retail/our-insights/the-beauty-market-in-2023-a-special-state-of-fashion-report
[16] Investor Deck – Page 21
[17] https://www.nature.com/articles/s41587-024-02166-7
[18] https://www.newswire.ca/news-releases/birchbiomed-is-cleared-to-begin-first-of-its-kind-phase-ii-clinical-trial-for-ground-breaking-anti-scarring-drug-674280503.html
[19] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5749507/
[20] See Page 11 from Investor Deck: https://www.grandviewresearch.com; https://www.marketresearchfuture.com/sample_request/8199; https://globenewswire.com/news-release/2020/12/09/2142566/0/en/Global-Alpoecia-Market-is-Forecast-to-Deliver-a-CAGR–of-5-1-Between-2019-and-2027.html
[21] https://www.fool.com/investing/2022/10/19/invest-1000-johnson-johnson-ipo-1944-how-much-now/
[22] https://www.macrotrends.net/stocks/charts/PFE/pfizer/stock-price-history
[23] Investor Deck – page 16
[24] https://www.cihi.ca/en/national-health-expenditure-trends-2022-snapshot
[25] https://www.fool.com/investing/2022/10/19/invest-1000-johnson-johnson-ipo-1944-how-much-now/
[26] https://www.entrepreneur.com/finance/why-founders-are-turning-to-reg-a-and-cf-to-raise-money-in/468339
[27] https://markets.businessinsider.com/news/stocks/birchbiomed-is-cleared-to-begin-first-of-its-kind-phase-ii-clinical-trial-for-ground-breaking-anti-scarring-drug-1016018500?op=1
[28] https://www.grandviewresearch.com/industry-analysis/scar-treatment-market
[29] https://addx.co/insights/why-private-markets-tend-to-outperform-public-every-time-even-in-down-markets/